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Proteins: 
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CHAPTER I 
PROTEm BIOSYBTHESIS 
:r 4"''>-)~'f'''i ._.," " _ Lt, .~e:>~<.n, .• ~.,s::\ ••. ,!.! ,.-...., ... ,~ 
The atudy at proteina and at their metabolic pathways haa 
been very extensive due to the tact that they are second only to 
nucleic acids in importance in the formation and well-being of an 
organism. Beside. making up most at the non-ake1etal structure 
of an organism# proteina, in the form of enzymes and hormone., 
constitute the main controlling mechanism at growth and develop-
ment. Almost every metabolic pathway known in living organisms 
is dependent on enzymes to make the chemistry thermodynamically 
feasible, and on protein or polypeptide hormones to control the 
extent of metabolism. 
Proteina are moderate to high molecular weight compoundS 
consisting mainly of amino acids joined by the head-to-tail 
condensation of many at each at about twenty amino acids. The 
condensation ot the various amino acids i8 between the carboxyl 
group ot one amino acid and the amino group ot another and 
involves the loss of one molecule ot water per peptide bond 
fo~ed. Thus, it can be seen that a peptide chain would hav., 
baSically, a tree amino group at one end at the chain and a fr •• 
carboxyl group at the other end. 
Since the structures of proteins are made up of many sub-
units (sometimes over 100) ot amino acids, there are two obvious 
possibilities about these structures. First, the chain could be 
a random sequence ot the any amino acids. Second .. the chain 
could be ·made up of a specitic .equence ot amino acids. The 
latter would .e •• the more likely .ince enzyme. and hormone. have 
specific functions to tultill which would most likely require a 
specific structure. The tirst positive proot of a speoitic 
structure tor a protein-came from Sanger et &1 (106). These 
.".."..~ 
workers elucidated the structure of insulin and showed that 
insulin had a .pecitic structural sequence of amino acids. Since 
that time, the complete amino ac1d sequences of several other 
proteins have been determined. 
The specit1c sequence ot amino acids is known as the primary 
structure ot a protein. Besides this primary structure, there 
are the secondary and tertiary structures. These are made up of 
the three dimensional structure of the protein chain and the 
intramolecular hydrogen and disulfide bonding. The intramolecular 
bonding i8 neeessary for protein activity. It tor example, one 
oxidizes the disultide bonds in insulin, activity is lost. Also, 
it one breaks the disulfide and hydrogen bonds of pancreatie 
ribonuolease, the protein chain completely untolds with complete 
loss ot activity. Adjusting the pH will cause reformation of the 
disulfide bonds with regeneration of eighty percent of enzymatic 
. 3 
activity (132). 
" 
The three dimensional structure ot proteins can be very 
complex. Protein chains are twisted into helical structures 
due to the regular relative positions taken up by the atoms when 
they are in covalent combination with each other. These fixed 
bond angles cause the adaptation ot a helical configuration. 
This is the a-helix# an extremely stable conformation, described 
by Pauling and Corey (94), and its formation is only possible 
due to the ihvariable occurence ot only the L-isomer ot amino 
acids in proteins. Besides this secondary ~tructure of proteins, 
the protein chains also adopt contorted tolds due to the some-
what irregular nature of the helices. This folding .eems to be 
inherent in the amino acid sequence so that no additional genetic 
information appears to be required to specify its nature. 
Nucleic Acids: 
1t".""L),,,.~~ , l~_, ,.S;.g . ."., .• 
The structure and role of nucleic acids have only been 
realized within the past decade. While the complete structure. 
of nucleic acids have not been elueidated, a general structure 
has been tormu1ated. Also, the mechanis. involving the role of 
nucleic acids in protein biosynthesis has been proposed and 
proven. 
Two clas.e. ot chemically distinct nucleic acids have been 
found: deoxyribonucleic acid (DBA) and ribonucleic acid (RNA). 
· 4 
These are both found in animal and plant tissues and in micro-
organisms. The DNA is found in the nucleus or nuclear region 
of the cell while the RNA is found predominently in the cyto-
plasm. The ohemical ditt,rence between these two compounds is 
that DNA contains 2'-deoxyriboae in it. structure while RNA has 
ribose in.tead. 
The nucleic acidl are formed by the head-to-tail condensatiOI 
ot many sub-units ot nuoleotides. A nucleotide 1s compo.ed of 
a sugar, either ribose or deoxyribose, a base attached to carbon 
one ot the sugar, and a ~hosphate .ster at carbon five. There 
are tive common baae. tound in the nuoleic acids. There are two 
purines, adenine and guanine, and three pyrimidines, cytOSine, 
thymine and uracil. Thymine is found almoat exclusively 1n DNA 
and uracil, tor the mOlt part, il found in RNA. The structures 
of the five bases and one ot the nucleotides are shown in Figure 
I. The linkage between the sub-units ot nucleic acids is a 
phosphate eater bridge between the 3' and 5' position. of the 
sugar. A Tepre.entation ot part ot a nucleic aoid chain is 
given in Figure II. 
, 
Although the structures ot the two compounds are quite 
Similar, their oellular roles are quite dift.rent. A. mentioned 
befor', DNA 1s found 1n the nucleus of the oell, unless no dil-
crete structure ot this type is pre.ent. However, it always 
forma part ot the genetie material, the chromosomes. The ehromo-
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somes contain long linear segments of DNA, discrete portions ot 
whieh constitute the hereditary determinants or genes of the 
eell, in com~ination with basic proteins, the histones. The 
histone. may be the regulatory .echanis. of controlling the 
activity ot the gene.. This could be the reason tor the 
differentiation of cells. Ribonucleic acids 'may a180 be found 
1n combination with basic proteins such as 1n the ribosomes. 
Thre. distinct type. of RNA have been found. One, the ribosomes, 
play an i.portant role in protein synthesis. Another is a low 
moleeular weight RIA which is called transter RHA. This carries 
amino acids to the.ita ot protein synthesis. The third type 
1s messenger RNA Wb1l.ch 1 a."the t8Dlplate tor protein synthesis 
and carrie. the genetic information trom the DNA. 
Analysis ot the structure ot DNA showed that tor every 
moleCUle of thymine there was one of adenine and tor every 
cyto~ne there was one guanine (24). From this knowledge, and 
from X-ray crystallography studies (126), it has been shown that 
. 
DBA is a twin-stranded, double helical structure, stabilized 
by hydrogen bonding between the base paira thymine-adenine and 
cytosine-guanine. Of the three types ot RNA, both transter RNA 
and mesaenger RNA have the same base ration relationship. 
Messenger RNA i8 made on a DNA template and remains in a sing1e-
stranded. configuration. Tranater lUiA 1s probably made in a 
similar manner and torms a paired helical structure by tolding 
'8 
back on itself (114). 
Thus, there are tour classes ot nucleic ac1ds: DNA, r1bo-
somal RNA, messenger RNA (m-RlfA) and transter RNA (t-RNA). They 
- -
all have spec1tic function. to perform in the synthesis ot pro-
tein. A d1agramatic sch .. e ot the stages in prote1n b10synthesis 
and the roles played by the nucleic acids 1s given in F1gure III. 
The follow1ng sections w111 attempt to present what is now known 
about the so .... call.d "Class1cal Mechan1sm" of protein biosynthesis 
The formation of the peptide bonds ot a prote1n i8 an 
energy requiring proces.. The energy required tor the proce.s 
can be provided by many mean.. It one take. a mixture ot amino 
acid. and heat. it, there will be a spontaneous polymerization 
ot the amino acida with the tormation ot peptide bonds. However, 
this process is a random one with many unwanted side reactions. 
Chemical method. to torm peptide bonds usually involve deriva-
tive. ot amino acid. which involve the activation ot one ot the 
group. on the amino acids. Thi. i. the ease in the living cell 
where ATP 18 used to activate the carboxyl group ot the amino 
acid. 
The ATP moleeule i. a high energy compound having two di.-
tinct reactive centers, at the two phosphoanhydride linkages. 
AA +ATP--.. 
Transfer RNA 
Completed 
Protein 
Activating 
Enzymes 
Release 
Enzymes 
·9 
~---.AMP + PP 
Transfer RNA-AA 
Transfer 
Enzymes Coded 
~ Ribosomes 
I 
Ribosomes 
FIGURE III: DIAGRAMATIC SCHEME OF THE 
STAGES OF PROTEIN BIOSYNTHESIS 
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The linkage adjacent to the adenosine monophosphate is the one 
which is actually involved, and is the source of the energy for 
the activation of the amino acids. The energy trom this bond 
is transferred to and conserved in the formation of a mixed acid 
anhydride bond between the AMP and the carboxyl group of the 
amino acid. Thus, it il at the expense ot the chemical energy 
of ATP that peptide bonds are formed. 
The us. of radio-labeled amino acids gave the tirst clue to 
the requirement at ATP tor protein biosynthesis. It was found 
that living cells could take up amino acida trom their surround-
ings and incorporate the. into protein. It w •• also found that 
ruptured cella could do this. However, it bee .. a apparent that 
AD was neeessary tor this activity. Thu" inhibitors ot ATP 
formation in calls such as arsen1te or 2,4-din1trophenol could 
prevent th1s incorporation (19). The u.e ot high speed centri-
fuge. made it po.,ible to 1s01ate distinct tractiona ot d1s-
rupted eells. The microsomal fraction, which is obtained as a 
sedi.ent at 100,000 x gravity, wa' found to be the most active 
in protein synth'sia, it supplied with the soluble supe.rnatant. 
This sYltem, however, was only active it either oxygenated 
mitochondria or exogenous ATP were supplied, and incorporation 
ot labeled amino acid. continued beyond a ten minute period only 
it an ATP generating system was provided (142). 
The A'1'P requlr .. ent shown above sugge.ted--an activation 
'11 
step involving ATP and amino acids. The activated compounds 
could not, however, be isolated. The first reports on the 
mechanism and measurement ot A'l'P activation of amino acids came 
in 1955. Hoagland (55), using supernatant fractions trom animal 
tissue, and DeMoss and Novelli (36), using mlcroblal cells, 
found that labeled inorganlc pyrophosphate (32pp) could exchange 
labeled phosphorous with ATP in a reaction that required the 
participation of amlno acid (AA). This suggested the followlng 
equilibrium: 
AA + A'1'p32 .. !A-AMP + 32pp 
This equilibrium can be established only it tlorid. ions are 
present to prevent the removal of pyrophosphate by pyrophos. 
phatase. pyrophosphate s •• ms to inhlblt the natural acceptor of 
the actlvated amino aclda. 
It one adds amlno acidl and ATP to a lupernatant, they 
react to give AA-AMP and PP. When equllibrium hal been reached, 
the rever.e reaction i. going on just al faat as the toreward 
reaction. Thus If 32pp 1. added, lt equilibrate. with the ATP 
torming an equilibrium concentration ot ATP32. This can be 
estimated atter isolation ot ATP trom the equilibrated system, 
thus the amount ot·32pp exchange, and the amount ot amino aeid-
adenylate present can be determlned. Each amino acid tound in 
protein can be separately activated to its own extent, and adding 
a large excesl ot one amino acid doe. not prevent .additional 
·12 
32pp exchange on the addition ot another amino acid. Thus, each 
amino acid hal its own activating enzyme since no competitive 
inhibition il .een (55) . 
. , 
The activated amino acids could not be isolated trom crude 
systems. Theretore, other approaches had to be undertaken to 
prove the structure ot this complex. Karasek et !l (65), and 
~,."., 
.. 
Kingdon ~~ a1 (66) isolated large amounts ot purified tryptophan-
. .. 
activating enzyme and prepared the corresponding amino acid 
adenylate. The product was released by mild denaturation of the 
enzyme and tound to be identical with a synthetic tryptophan 
adenylate. DeMOss !l al (35) also tound that synthetic amino 
.~ 
acid adeny1ates oou1d produce the 32pp exchange reaotion in. a 
cel1-tre. system. Hoagland et al (56) and Bernlohr and Webster 
~~
(13) proved the structure ot the AA-AMP complex. They used the 
heavy isotope ot oxygen, 180, as part ot the carboxyl group ot 
tryptophan. Cleavage ot the AA-adenylate gave rise to an AMP 
which wal labeled. The reaetion was as tollows: 
i ~ ROO i . I II ~ 
R~-CH-C-018_K + ATP ..,t. H21-CH-e-018_p-Adenosine + pp 
I 
OK 
+JfHaOH 
8 
Q 
801 --~--Adenoslne 
OH 
·13 
The label could be found us1ng a mass spectrophotometer. These 
exper1ments proved that there was a def1n1tecovalent bond 
between the am1no acid and AMP 1n the complex. 
Several general statements can be made about activating 
enzymes: 
1. ATP is the only nucleotide triphosphate which is used 
tor the activation so the bind1ng s1te is specific for aden1ne. 
2. Each activating enzyme b1nds ATP and its own specific 
amino ac1d on separate site •. 
3. Mg++ ions are necessary tor the reaction and ~ are 
somet1me. required. 
4. The pp trom the ATP h1nders the approach ot the natural 
acceptor (t-RlA) of the act1vated amino acid. 
5. Activ1ty is dependent on thiol groups. 
The spec1f1city of the act1vating enzymes 1s now known not 
to be very high. For example, the isoleucine activat1ng enzyme 
from E. Co11 can also activate valine to a s11ght degree (12). 
~~
Conversely, valine activation by va11ne activat1ng enzyme 1s 
1nh1b1ted by isoleucine (11). Also, some amino acid analogues 
can be activated by the appropriate enzyme (30). 
As was ment10ned betore, the am1no ac1d-AMP complex could 
not be isolated and in tact, still cannot be. This is because 
it remains firmly bound to the activating enzyme until its 
natural acceptor is able to release it. It is now known that a 
·14 
particular class of ribonucleic acid, transfer RNA, is the 
natural acceptor tor the activated amino acids. The role of 
t-RNA is discussed in the next section. 
The Bature and Role of Tranafer Ribonucleic Acid: 
~ ,,4",4,,><. ~.............., ~ "~~·~,,Jf"'" ", '. , .. ,~-A.(, .,"",,~..,. •. ,$<, '" .,1 
Transfer ribonucleic acids are relatively small compared to 
other types of nucleic acids. They have a molecular weight of 
about 25-30 thousand which corresponds to about 80 nucleotides. 
Recent X-ray diffraction data (114) have shown that the molecules 
, 
bend back upon themselves in a hairpin fashion rather than being 
linear. The gross bas. eomposition agrees with this in that 
there is a 1:1 corr •• pondence between base pairs (112)(92) which 
.. 
would allow ba •• pairing to stabilize the hairpin structure. 
The nuc1eotides around the hairpin bend are unpaired, and it is 
thought that this i. the site ot recognition of the t-RNA by 
either the activating enzymes or the messenger RNA or both • 
• 
The sequences ot nuc1eotides in t-RNA have not been eluci-
dated, but it has been shown that the terminal sequence ot all 
t-RlA's is the same. This terminal sequence is as tollows: 
~ 
RRA--3'p5'--cytidylyl--3 t p5 1 --cytidy1yl--3 t p5 t --AMF 
This terminal sequence is absolutely necessary tor activity and 
the amino acids can only be linked to the final nucleotide. 
Studies on the structure ot t-RNA have also revealed the 
presence ot up to 15 percent ot the total ot abnormal bases. 
.15 
Two to four percent ofpseudouridylic acid have been found. 
There is evidence that there is a correlation between the con-
tent of this base and the amino acid binding ability, at least 
of leucine, at a preparation of t-RNA tram yeast (93). 
~ 
Methylated bases, torming up to ten percent, have also been 
found. These include thymine which is normally associated with 
DNA. The funotion of these methylated bases is not known, but 
it haa been shown that they do not randomly replace the normal 
bases, but are clustered around the center ot the molecule (141). 
Although they are not required tor binding amino acids (115), 
they could playa part in the eoding requirement. 
Transter RNA is much more specitic than the activating 
enzyme. Although as mentioned betore, the isoleucine activating 
enzyme of E. Coli can slowly catalyse the tormation at valyl 
~~
adenylate, only isoleucine residue can be transterred to t-RNA 
(12). Recent studi.s have detined the degree or speciticity 
of t-RHA. The amino acid analogue alloi.oleucine may substitute 
tor isoleucine onoe In .. twenty time. and tor valine onee in three 
hundred showing that the ability to reject unnatural analogues 
is relatlvely low. However, natural amino acids were tound to 
substitute tor each other less than once in ten thousand times 
(70). 
The transfer of the amino acid from the AA-AMP complex to 
the t-RNA is eatalysed by the same activating enzyme. The action 
16 
of this enzyme i8 shown below: 
AA )E( ATP . )E( t .. RNA-AA 
PP E-AMP-AA t-RKA 
+ AMP 
This t-RNA-AA complex i8 stable at acid and neutral pH, but is 
cleaved by treatment with 0.01 N alkal1 for five m1nutes at room 
temperature. The aaino acid is joined to the terminal adenos1ne 
residue of t-RNA by means of a reactive ester bond of the 
following type: 
The linkage is thought to be an ester linkage and it is thought 
to be at the 3' rather than the 2' hydroxyl group ot the ribose 
because ot the tollowing evidence. First, the bond il not as 
reactive as that ot the AA-AMP bond ruling out combination with 
the tertiary phosphates ot intranucleotide phosphodiester bonda 
ot t-RNA. Second, periodate reactivity ot t-RIA is restored 
atter cleavage of the activated bond with alkali. Direct evi-
dence at this came tram isolation ot the terminal adenos1ne re-
sidue loaded with AA (42)(140). pancreatic ribonuclease will 
cleave oft this terminal adenosine at t-RNA even when in com-
bination with an aaino acid. Electrophoretic mobilities and 
ehemical reactivity have shown this complex to be identical with 
synthetic models~ 
17 
The fate of t-RNA-AA added to cell-tree preparations can be 
followed using cl4 labeled amino acids. The label can be seen 
to disappear from the t-RNA traction and appear in the micro-
somal or ribosomal fraction in five to ten minutes. Later, the 
label can be found in free protein. A typical time curve exper-
iment is shown in Figure IV studies have shown that t-RNA~AA 
compounds are major intermediates in the synthesis of protein in 
the cell using pulse labeling (short periods of incubation with 
radio->l abe·' ed amino acids followed by incubation with unlabeled 
amino acids), 
Transfer enzyme. have now been prepared tree trom activating 
enzymes (81). They can be found in loose association with the 
microsomal or ribosomal.fraction, but are maInly isolated from 
the supernatant traction ot the cell. It 1s not known whether 
there are separate transter enzymes tor each amino acId, but 
this seems unlikely. Two enzyme systems have been isolated from 
rat liver (45)(46)(47), named transteras8 I and transferase II. 
The tormer transfers amIno acids from t-RRA-AA to mlcrosomes; 
together they transfer AA to ribosomes. Atter tranSfer, the 
amino acid joins to the end of the growing peptide chain and the 
t-RNA, liberated by the combination ot the following t-RNA-AA, 
eventually recycle. back to the soluble traction and brings 
back another amino acid to the ri~osome. 
The inhibition ot protein biosynthesis by puramycin s •• ms 
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19 
to be involved with the t-RNA-AA step of synthesis (121). ~his 
-
compound can be considered to be a structural analogue of t-RNA 
(See Figure V) and it causes the release of untinished, soluble 
peptides from ribosomes in all cell-tree systems. It accom-
plishes this by joining with an amino acid and then substituting 
for t-RNA-AA by joining the end ot the growing peptide chain. 
peptide chains grow from the free amino end by singular additions 
of activated amino acids of t-RNA-AA. As the peptide chain 
grows, it is held on the ribosome by a t-RNA, the last one to 
arrive. This is done, presumably, by base complementation 
between the t-RNA and the m-RNA. Puromyein-AA displaces thfs" 
terminal t-RRA and, lacking the polynucleotide structure of 
t-RNA, the terminal puromycin tails to hold the peptide chain 
to its 'site. Isolation of small peptide. was additional evi-
dence of puromycin'S mode of action. 
Ribosome. isolated from various sourees have a reasonably 
constant composition. They all contain about 40 percent RNA 
and 60 percent protein. The protein mOiety consists of aggre-
gates of rather low Dlolecular weight, 1.5 to 50 thousand, and 
contains large amounts of basic and dioarboxylic amino acids, 
with half of the latter in the amide torm. The large negative 
charge of the RIA outweighs the positive charge of the protein 
puromycin 
20 
Transter-RNA-AA 
Complex 
FIGURE V: COMPARISON OF THE STRUCTURES OF pUROMYCIN 
AND TRANSFER-RNA-AA COMPLEX. 
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whiCh leaves a net negative charge on the ribosomes. 
Ribosomes are aggregate. of sub-units. The ribosomes are 
generally classified according to their sedimentation constants 
in a density gradient field. This constant is the sedimentation 
rate in a unit centrifugal field and is expressed in Svedberg 
units, equal to 10-13 sec.. Ribosomes of 80S are usually 
observed except for bacteria where 70S particles are found. 
These partieles can be broken down into sub-units of one 60S 
and one 4Os, and one 50S and one 30S respectively. This disso-
ciation occurs when the Mg++ ion concentration is drastically 
lowered. 
The ribosomal RNA il allo made up ot sub-units. The sub-
units '60s and 50S contain 28-308 RNA while all the partieles 
contain 16-188 RNA. The ribosomal RNA does not in general tollow 
the baae complementary pattern (1:1 ration ot base pairs) tound 
in other nucleic acids (127). This brings up a question ot the 
origin ot this eompound. Portions ot the DBA ot E. Coli contain 
~;.",. 
sequences complementary to the ribosomal RNA ot that strain (137) 
(138). On a quantitive baSiS, tor Bacillus megatherium, it has J.., ..... ,.. . . ".iI.· .,,,.it.,, ·'k' 
been reported that there are ten cistrons of the gene specitic 
tor the 238 portion of ribosomal RNA and 45 tor the 16s portion 
(139). 
The ribosomes in themselves ~re inactive in protein syn-
thesis. It is only in combination with a strand ot messenger 
·22 
RNA that they can be active. More than one ribosom., in tact, 
is associated with each molecule ot m-RNA; these are called 
polysomes. 
The ribosome as part o~ the polysome i8 the site ot pro-
tein synthesis. The ribosome travels along the strand ot m-RNA, 
which contains the genetiC information from the DNA, and picks 
up the amino acids specitied by the m-RNA. The growing poly-
peptide chain remains attached to the ribosome via the last 
t-RNA until the completed protein is released. The ribosome 
then eycles back on the m-RKA to produce another protein. 
Stepwise synthesis (chain lengthening by one amino acid at 
a time) was thought to be unlikely until fairly recently. This 
process was proved by successfully demonstrating unequal label-
ing. Use ot cell-free systems, which incorporate amino acids 
much more slowly than in intact organisms, provided a system to 
demonstrate this. Systems using living reticulocytes (88)(16) 
. 
produced unequally labeled hemoglobin. Short periods of label-
ing (pulse labeling) with l4C-valine were employed (tour minutes) 
so that many protein chains might be labeled while yet unfin-
ished. Completion of the chains could then be made with un-
labeled amino acids. subsequent, isolation of the protein hemo-
globin was followed by partial hydrolYSis, paper electrophoresis 
and chromatography ot peptide fragments. The hydrolysis pro-
ductl of hemoglobin are well known 10 that the finger prints ot 
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the peptide fragments of the labeled hemoglobin could be related 
to definite portions of the complete hemoglobin molecule. The 
specific activity of the labeled amino acid was found to be 
grossly ditterent 1n two olthe peptides. The specific activity 
was also found to increase with proximity to the amino end of the 
chain, prov1ng that the amino acids atth1s end were being put 
into position during the initial period of high radioactivity. 
This therefore proved the stepwise synthesis. 
~.~.~l]1t!;iZ1!:A t':2~:,,;'~ ?!~tJ~l 
Deoxyribonucleic acid. are the largest ot all classes of 
nucleic aoids. They are twin-stranded, double helical structures 
of enormous molecular weight, in fact, about ten million. They 
exist in the nuclear region ot the cell in a highly coiled con-
formation. The DNA, in combination with basic prote1na, the 
histones, make up the chromosomes ot the cell. Discrete portions 
of these chromosomes are the units ot cellular heredity, the 
genes. 
The sequence of bases in DNA cannot be elucidated with 
present day techniques. These huge molecules are very easily 
degraded, even by the shearing forces involved in mixing. This 
would present a major problem in simply obtaining a singular 
molecular species. Then, even it one species could be obtained, 
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the immense sise of the molecule would be of impractical chain-
length as tar as chemical procedures are coneerned. 
The proteins which are connected with the DNA may have some 
part in regulating the aetion of the DNA. Differentiation ot 
the cells of the embryonic organism results in the masking ot 
many genes of the chromosome.. The removal ot arginine-rich 
histones from the cell nucleus results in an increase in the 
synthesis of messenger RIA, and even in the appearance at new 
species of this substance. The lysine-rich histone. are rela-
tively inert (4}(59). 
-The reproduction or synthesis of new DXA 1s essential tor 
cellular div1s1ons. The f1rst reports on the mode ot replication 
at DNA came in 1958 (82). The.e workers grew E. Coli 1n a 
~ J,.c.,,<,. 
medium contain1ng l5.lH4Cl, as the only source ot n1trogen. This 
meant that the DNA would all be labeled with 15M. The bacteria 
were then grown for one generation period (division time) in 
l~H4Cl. The bacteria were collected and the DNA was subse-
quently isolated. It was shown that most of the DNA consisted 
ot hybrid molecules, halt ot each molecule containing 14.N made 
in the tinal division cycle and the rest having 15» character-
istic of the parent generation. Isolation and identification 
could be oarried out aince 15.N-DNA and l~_DKA are of different 
density allowing their separation by density-gradient centri-
fugation. These 15N_I~ hybrids were not lost during further 
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growth in l4NH4Cl , but were gradually diluted with l4.N_l 4oN 
daughter form. 
The simplest interpretation of these experimental findings 
is that replication of DNA involves separation of the strands 
of the double helix, and that synthesis of new complementary 
strands occurs on each of the parent strands. Tnesequence of 
the new strand would be complementary rather than identical and 
would be dictated by adenine-thymine guanine-cytosine pairing 
of the daughter with the parent strand. 
In spite of the simple interpretation of the above work, 
many workers believe that uncoiling of the double helix would be 
too lengthy a process to occur in the cell. One group of workers 
(26), have reinterpreted the above findings a8 the actions of 
twin double-helices breaking down into individual double-
helices. .owever, the mechanism of base complementation is more 
difficult to visualize it a double helix is to be built upon an 
already existing double helix} presumably hydrogen bonds would 
have to be broken temporarily without the strands unwinding. 
In vitro, DNA polymerase u.ses the single stranded helix (l09), 
~ _~,dld~~"kA .. 
but the double strand could be used in vivo. RNA polymerase 
.-.. ,,~ 
can us. either a single or double stranded helix in vitro. 
~ ")*tt;:::;:m,J,.,~X 
Thus, if RNA can be built upon a double stranded DBA template 
in vivo, so could DNA. At the present time, the mechanism 
---
could be elther of the two mentioned, but evidence leans toward 
the single strand mechanism as being more probable. 
Normal cellular division (mitosis) in higher organisms 
involves the duplication of the chromosomes as a salient feature. 
Replication of DNA takes place to provlde an ldentical comple-
ment of this substance tor the daughter cell. Reductive dlvision 
of certain cells is a somewhat different process (melos1s) and 
here the DNA of'the resultlng gametes (sex cells) is half that 
~ 
of the normal cell ot the organlsm. Fusion ot the male and 
temale gamete., each containing half portions of DNA, returns 
the level to normal tor the development ot the embryo. 
Inheritance ot certain charaoteri.tics by the progeny 
follow. certain well detined pathways. Clas8ical genetiCS, 
baaed upon the work of .endel in the nineteenth century, carries 
the basic concept that each character of an organism la a dis-
crete entity controlled by one gene palr. Thi. reters to di-
ploid organisms where chromosomes otten occur in analogous pairs 
except in ,ex celli or gametel. Each ot the gene pair. lies on 
homoiogou. chromosome. and are known .s allelea or allelomorphic 
genes. One ot this pair can be ettectlve in causing the appear-
ance ot it' corresponding characteristic (phenotype) in the 
-
organism, the other being ineftective. These are therefore 
called the dominant and recessive forms respectively, and the 
organism ls heterozygous for this character. During melosis, 
segregation occurs, separating each member of an allelomorphic 
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pair into different gametes. Each gamete possesses only one of 
each homologous pairs of chromosomes and so has half the diploid 
total. Two gaJllete. combine after mating restoring the diploid 
form for the offspring. Thus, the mating of two organisms, each 
heterozygous for the same dominant and reserve characteristic, 
will, on the average, produce three out of four offspring with 
this characteristic. The fourth, or double recessive, will not 
have this characteristic (127). 
Recognition ot the association ot the action at genes with 
certain enzymatic reactions led to the one gene-one enzyme 
hypothesis. This hypothesiS suggested that one gene controlled 
both the structure and regulation of one enzyme. Today, this 
hypotheSiS is one cistron-one protein chain. It is now known 
that one gene·.controls the structure of a protein, via messenger 
RNA, but other genes regulate the syntheSis at this protein. 
The role at DNA in protein syntheSiS is therefore to con-
tain and pass on cellular genetiC information as to the specific 
structure at proteins and to regulate the synthesis ot these. 
proteins. The DNA passes on the genetiC information via messenger 
... ; 
RNA. It has been shown that m-RNA is synthesized on a DNA tem-
plate. An enzyme system trom rat liver was found that incorpor-
ates nucleoside triphosphates into RNA (128)(129). Similar 
~ .. 
systems have been isolated from bacterial and higher plant sys-
tems. Two to eight-fold increases in RNA have been obtained 
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in vitro. DNA is an absolute requirement in these systems. 
Ribonucleotides are selected by base complementat1on with the 
DNA. This complementation can be demonstrated us1ng the bio-
synthet1c homopolymer, polydeoxythymad1lic aCid, as primer. Only 
adenOSine monophoaphate 1s incorporated rrom a m1xture ot nucleo-
side tr1phosphates (48). Similarly, us1ng a deoxyadenylic-deoxy-
thymidyl1c ac1d ~opolym.r as primer one gets a copolymer of 
uridylic and adenylic acids. 
Function of Messenger RIA: 
,& ... ,.-44%4 ; .WS'4'" ~ ~J;;;C,,·!4¥;AZ* ..... r",($JI~L, ... ~ ~,"J~,emt 
Early reterences on protein synthesis showed some require-
ment for DNA. The DNA did not see. to playa direct role in 
this process in cell-free systems from animal and higher orga-
nisms but was necessary tor activity in micro-organisms. Obvious 
ly, the machinery for protein synthesis was more labile in 
micro-organisms and DNA was still required to organize the cyto-
plasmic ribosomes. It was suspected that RNA might be the inter-
mediary between DNA and protein synthesis. The first direct 
evidence tor this came trom experiments involving bacteriophage 
(virus.s which attack bacteria). 
Immediately after intect10n of E. Coli with phage, rapid 
~.t.- .• ".--. 
incorporat10n of 32p into ribonucleic acid occurs (123)(8). No 
net increase in RNA could, however, be detected so that synthe-
sis must have been followed by rapid degradation.'" pulse label-
in w1th 32 allows onl labeled s eeies of RNA to 
29 
pick up radioactivity. The study of this labeled species of RNA 
showed it to have a composition distinct from any other species 
of RNA in E. Coli. Moreover, it ressembled the DNA composition 
~~
of the infecting phage, not that of E •. Coli. This seemed to 
~, .. 
suggest that the new type of RNA, formed by the phage DNA, was 
the template for the synthesis of proteins necessary to the virus. 
" 
Thus, the specificity for protein synthesis comes not from the 
ribosome. but from this new type, or meas.nger RNA. This was 
proven by the observation that the bulk. ot the incorporated 32p 
could be tound in the ribosomal fraction ot the cell, provided 
that the concentration ot Mg++ i8 about lO-2M; lowering the 
concentration of Mg++ to lO-~, which will dissoeiate the poly-
somea, liberated the label into the soluble fraction (91). 
Further proof that it was m-RNA that was synthesized and 
not ribosomal RNA came from the following work (21). Bacteria 
were grown in a medium containing 130 and 15.N 10 that cellular 
constituents would be denser than normal. Infection with phage 
along with pulse labeling was carried out in a medium containing 
the normal elements 120 and l~. The labeled RNA was tound to 
be aasociated with heavy ribosomes, so it was concluded that no 
new ribosomes (light) were formed. 
-, 
Use of foreign m-RNA finally proved the role of this species. 
An outstanding examp.;.e of using a foreign m-RBA is the use of 
synthetic polynucleotides.. Thus, polyuryl.idylie acid stimulates 
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the formation of polyphenylalanine peptide chain. Also, ribo-
nucleic acid, isolated from bacteria can cause the appearance of 
a new type of protein in a. culture of chick embryo cells. ,This 
protein ressembles that normally tound in the donor bacteria (5) • 
. 
Finally, the additi9n ot RNA :tram-liver caused tumor cells to. 
synthesize proteins such as serum albumin which normally are 
found in liver but not in the tumor eells (90) • 
.. 
The site of action at m-RHA is at the ribosome. Several 
ribosomes are held together by a strand at m-RNA. This aggregate 
is called the polysome. The m-RIA provides the genetic intor-
mation, and the ribosome the apparatus for the synthesis ot 
specific protein chains. The amino acid-t-RNA complexes approach 
the messenger RIA template and the correct one is selected by 
interaction between the two species. 
Thil interaction between t-RNA and m-RIA was suggested in 
1958 a8 the adapter hypothesis by Orick (32)(33). This hypo-
thesil stated that m-RNA may recognize, not the amino acid, but 
its respective t-RIA. 
a natural system (38). 
This adapter role has now been proven in 
Transfer RlA.140-cysteine was isolated 
from E. 0011. The t~RlA_l4C-cysteine was converted to t-RNA-l4C-
......... 
alanine by reduction ot the amino acid with Raney nickel without 
disruption of the ester bond between the amino acid and terminal 
residue of t-RNA. Rabbit hemoglobin was prepared in a cell-tree 
system using rabbit reticulocyte ribosomes and the labeled t-RNA-
31 
alanine. It was found that the labeled alanine was incorporated 
into a peptide fragment from the chain which normally contains 
cystine but no alanine. On the other hand .. no radioactivity was 
found in another peptide fragment known to contain alanine. 
Therefore, it must be the t-RNA and not the amino acid which is 
recognized .. 
The m-RNA, a strand about lO-15~ in .diamet.r, are threaded 
through ribosomes lying some 50-l50~ apart (50). The m-RNA move. 
relative to the ribosome. revealing one piece of genetic infor-
mation after another. Finally, the ribosome, with its completed 
peptide chain is relea.ed. 
It is now believed that the completed protein chains are 
released from the ribosomes and spontaneously arrive at the 
natural folding configurations determined by their .equence ot 
amino acids. Certain other structural modifications may be 
necessary to bring the protein to its functional state. Thus, 
intra- and inter-molecular disulfide bone)s would have to be 
tormed, perhaps by disulfide interchange .reactions with oxidized 
glutathione. Also a limited proteolysiS may be necessary to 
promote activity. 
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CHAPTER II 
THE BIOCHEMISTRY OF THE HYPOGLYCEMIC COMPOUlmS 
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Diabetes mellitus is a chronic metabolic disorder characte~ 
ized by a disturbance ot carbohydrate, lipid and protein metab-
olism. It is manitested by a decreased ability to utilize car-
bohydrates, an increase at ketone bodies, and decreased protein 
synthesis. This condition 1s due to either an inadequate supply 
at insulin or a malfunction in the organism with the result that 
the hormone cannot be utilized. 
It became apparent in 1889. when Merig and Minkowski (81) 
showed that pancreatectolllY produced diabetes mellitus, that 
this gland produced .ome hormone which controlled carbohydrate 
metaboli.m. In 1922, Banting and Best (9)(10)(11) succeeded 
~ ". 
in alleviating the symptoms ot diabetes. The complete structure 
,. 
at insulin was elucidated in 1955 by Sanger et al (106). 
~~
.. 
Sinee insulin is a protein hormone .usceptible to many 
torms at denaturation, and since it cannot be taken orally, much 
r ••• arch has been directed toward tinding oral hypoglycemic 
compounds. In 1926, Frank, Borthman, and Wagner (43) reported 
that a biguanide, synthalin, had hypoglycemic properties. Fur-
ther study at this compound by Graham and Linder (52) showed 
that it caused severe liver damage and it was theretore soon 
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For many years, local remedies tor diabetes mellitus, made 
trom plant extracts, had been used around the world. Allen (3) 
investigated blueberry leat extracts and Hugh-Jones (60) studied 
extracts ot periwinkle, mistletoe and niokerberry. The alkaloid 
galepine was tound by Muller (86) to reduce blood sugar ot both 
normal and diabetic man. Clementi (29) found that another plant 
-
alkaloid had similar ettects. Other agents, such as gluQokinen 
(31) extracted trom clams, and an extract trom the diSintegration 
product ot killed bacteria (69A) were found to have an hypogly-
. 
cemio ettect. Most ot these were tound to cause liver damage and 
were soon forgotten as therapeutic agents. 
Hassall, Reyle and Fing (54) isolated a eompound called 
HYpoglycin A trom the trui t of a plant, ~)f~lh~~ ~~R~.d,. Anderson 
et al (6) and Ellington, Ha.sall and Plimmer (39) determined that 
-~ 
." 
the activity ot this agent came from an unusual amino acid whose 
structure is given in Table II. A second hypoglycemic agent 
isolated trom the same plant called HYpoglycin B, is a dipeptide 
of Hypoglycin A and glutamic acid (54). 
In 1942, Janbon, Chaptal, Vadel and schaap (62) discovered 
a synthetiC compound, 5-i.opropyl-2-8ultanilam1de-l~3-4-thio­
diazol. (IPTD) which eould lower blood sugar levels. This com-
pound was toxic to the point of tatality but it opened up a wide 
field ot intere.t in synthetiC oral hypoglycemic compounds. At 
about the same time that interest in the thiodlazoles was dying 
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out because ot their toxicity,' interest was renewed in this field. 
Franke, Acheli8, Betram!!~ (1)(15)(44) found that l-butyl-3-
sulfonylurea (carbutamide) possessed hypoglycemic activity. This 
too was found to be toxic, but many related compounds have sinee 
been studied in a search for clinically safe oral hypoglycemic 
agents (25}(19). 
Most ot the compounds studied have proven unsafe for clini-
cal use. However, three analogues ot carbutamide, namely tolbut-
amide, chlorpropamide, and metahexamide have been subjected to 
extensive clinical studies. The tirst two of these are now 
currently being widely used to control mild, adult diabetes 
mellitus. Two new arylsultonylureas, acetohexamide and tolinase 
have recently been di8covered, but only tolinase ahows any pro-
mise as an ettective clinical drug (22A)(53A)(116A). 
Carbutamide (H-butyl-N'-sulfonylurea) is a white crystalline 
. 
solid having weakly acidic properties. Thus, it readily forms 
water soluble salts with alkali and ia usually obtained as the 
sod.ium salt. The liver partially detoxifies this compound by 
acetylation and the resulting compound is slowly eliminated via 
the kidneys. Carbutamide as all the sulfonamides containing the 
p-amino group, has some antibacterial action and impairs the 
thyroid function. 
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Carbutamide 
Tolbutamide 
Chlorpropamide 
Methexamide 
Acetohexamide 
Tolinase 
TABLE' I: THE ARYLSULFONYLUREAS. 
The replacement at the p-amino group at earbutamide gives 
riae to the most widely used oral hypoglycemic agent at today, 
namely tolbutamide (N-butyl-H'-p-toluenesultonylurea, orinase). 
The change ot the substituted group on the para position at the 
benzine ring is responsible tor many important metabolic changes 
in the drug. The compound is insoluble in water but readily 
torma salts with alkalis. 
In man, tolbutamide is degraded by oxidation of the p-methyl 
group (72). The resulting carboxylic acid (B-butyl-lf'-p-carboxy-
.. 
phenyl sulfonylurea) is water soluble and completely non-toxic. 
Another degradation product (H-butyl-N'-p-hydroxymethyl phenyl-
sulfonylurea) has been isolated in very small amounts from blood 
(105). This may well be an intermediate in the oxidation to the 
-
carboxylic acid excretory product. FInally, Mohnike and 
Wittenhagen (84) isolated from the urine of dogs a toxic .eta-
,-
bolite of tolbutamide, p-toluen.sulfonamide, and another com-
pound which was later shown to be p-toluenesulfonylurea (85). 
Tolbutamide, unlike carbutamide, do •• not affect thyroid function 
(40) because of the removal of the p-amino group (74). 
Chlorpropamide (H-propyl-H-chlorobenaenesulfonylurea, 
niabenase) ditters trom tolbutamide by the replacement of the 
p-methyl by chlorine and ot the n-butyl group by n-propyl. The 
eftectivene.s at this drug is signiticantly difterent from that 
at tolbutamide. A single one gram do.e ot chlorpropamide pro-
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ducad a significantly greater hypoglycemic efteet in normal sub-
jects than did an identical dose of tolbutamide (131). The bio-
logical halt-llte of chlorpropam1de is approximately 35 hours or 
about ten ti.es that ot tolbutamide (117). Evidence indicate. 
that, 1n man, this compound do •• not undergo any appreciable 
metaboll •• pr10r to excretion by the kidneys. No detinite chroma-
tographic or ultraviolet absorption ditterence. have been tound 
between the pure drug and that round in s.rum or urine (64)(118). 
~owever) three difterent ohromatographic .pots were found using 
urine tram dogs treated with chlorpropamide-35s. These eompounds 
~ere identified as the unchanged drug, p-chlorobenzenesu1tony1-
~r.aJ and p-chlorobenzenesu1tonamide (64). As with tolbutamide, 
thyroid function 1s not impaired by chlorpropamide (113). 
Metahexamlde (fi-Cyc1ohexy1-N'-(3-amlno-4-to1uenesu1tonyl) 
~rea) ls very ettective as a hypoglycem1c agent, with a duration 
~t action which i8 longer than that ot chlorpropamide. It is 
_bout halt as ettective as chlorpropamide and tive times as 
_ttective as tolbutamide in producing sustained blood levels 
(67). Dogs and r$bbits excrete in urine 30 to 35 percent of the 
~d.ini.tered dose as the unchanged compound and 40 to 50 percent 
•• 3-am1no-4-benzenesulfonamide (104). Since it was found that 
~etah.xamide causes obstructive jaundice (13), the compound has 
peen abandoned as a c11nical drug. 
Acetohexamide (1-{p-aoetylbenzene.ultony1)-3-cyclohexy1-
urea), like all the other arylsulfonylureas. 1s insoluble. How-
ever, unlike the othe~8, the sodium salt of acetohexamide is only 
sparingly soluble in water. In duration of act1vity, acetohexa-
mide talls between tolbutamide and chlorpropamide (75) '. It is 
metabolized in the human body by reduction ot the p-aeetyl group. 
Both acetohexamide and its reduction products have hypoglycemic 
activity 1n man and antmals. This activity of its metabolic 
product prolongs the hypoglycemic activity ot acetohexamide and 
1s at least partially responsible for it. relatively long dura-
tion ot activity (130). 
Tolina.e (116A) (l-(hexahydro-l-azepinyl)-3-tolylsulfonyl-
urea) has just been released tor clinical use. The manutacturer 
says that the drug will be usetul to adult patienta who cannot 
use drugs previously on the market. 
The mechanism by which tolbutamide and the other arylsul-
fonylureas exert their ettect 1s still disputed. It is generally 
agreed that in mammals the.e compound. produce hypoglycemia only 
when some functioning pancreatiC beta eells are pre.ent. Houslay 
and Pennos (58) showed that the presence ot .o.e functioning 
panereatic tissue is essential for the hypoglycemic eftect of 
the arylsulfonylureas. The arylsulfonylureas reduce the tasting 
blood sugar level ot intact and partially pancreatectomized or 
mildly alloxan diabetic animals, but they do not do .0 after 
total pancreatectomy 1n dogs, rabbits, rats or man (83)(133), 
nor in animals made severely diabetic with alloxan. 
Evidence indicates that the administration of the.e drugs 
results in decreased pancreatic insulin (97), and increased 
inSUlin-like activity in the pancreatic vein (96)(99). However, 
. 
many ot the metabolic ettects which accompany ary1sulfony1urea 
induced hypoglycemia are $0 difterent from those which accompany 
insulin induced hypoglycemia that aome inve.tigators postulate 
the presence of major extrahepatic tactors of arylsulfonylurea 
action. 
Tolbutamide and chlorpropamide, added in vitro, using rat 
,..,. ;a 1 a-
liver slices, have been found to decrease epinephrine induced 
glycogenolysis (122) and ketogenesis (18). When rat liver homo-
genate. were used, tolbutamide was round to alter a number of 
enzymatiC activities, including at least one transaminase (17), 
several NAD and KADP requiring systems (118), and the phosphory-
lase reactivating syst.m (14). Tolbutamide and chlorpropamide 
administered in vivo decreased ketogenesis (20){22). Tolbutamide 
~~
administered in vivo, with the ettect .e.sured either in vivo or 
~·.:s;;;:tt,\W"'P ~~
in vitro, has been round to: a) deerea.e glucose output (108), 
~ ttut. Ulln 
b) increase the syntheSiS ot glycogen, fatty acids and protein, 
without the corresponding extrahepatic eftects •• en with insulin 
(102), c} decre ••• the conversion of fructose and galactose to 
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glucose (7){lOl), and d) alter the levels ot numerous enzymatic 
activities, including inereased activity of malic enzyme (124). 
Chlorpropamide may, under certain conditions, slightly 
increase the glycogen content of rat diaphragm, while under the 
same conditions tolbutamide has no effect (28). Ohlorpropamide 
also moderately depres.es glutamic-oxalaaetic transaminase 
activity in the livers ot well-ted animals (lOT). The.e scat-
tered reports are compatible with the hypothesis that the aryl-
sulfonylureas attect enzyme reactions which depend upon pyridine 
nucleotides as eo-factors. 
In 1926, Frank, Worthman and wagner (43) synthesized 
synthalin A atter earlier reports ~tated that the administration 
ot guanidine lowers the blood sugar concentration (125). After 
lim1ted clinical trials, thi. compound ~as tound to be tox1c 
producing histological change. 1n the liver and k1dney, and all 
further use was discontinued (15). 
In 1951, Shapiro, Parrino and Freedman (110) described the 
hypoglycemic ettect ot phenethylbiguan1de (Nl-beta-phenethyl-
to~1dinyll.lnourea hydrochlor1de, Phenformin, DBI). Atter 
investigating nearly two hundred derivatives ot termamidinyl-
imlnoureas, they round that phenethylb1guanlde was a highly ae-
tive oral hypoglycemic agent in both normal and alloxan diabetic 
animals, except in the ca •• ot the dog. 
H-W-C-O--(CH )-BH-Q-WIL 
cO' II 2 n II .'-"'2 
lfH NH 
H C--C---C--CH-OH--COOH 
3 \ / 2 I 
o ~ 
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Guanidine 
syntha1in A (n := 10) 
Synthalin B (n :;; 12) 
Phenethy1biguanide 
Hypoglye1n A 
Hypoglyein B 
IPTD 
TABLE II: GUANIDINE AND SOME DERIVATIVES. 
4
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The mode of action o~ phenethy1biguanide differs markedly 
from that of the ary1su1fonylureas as evidenced by the facts 
that this compound is an eftective hypoglycemic agent in pan-
createctomized animals (89), in severe alloxan diabetes (120) 
and in patients with juvenile or insulin deficient types of 
diabetes (98). Evld.ently .. phenethylblguanide does not require 
that tunctional pancreatic tissue be present; this exclude. the 
the possibility that it acts by stimulating the beta cell. to 
produce more insulin a8 has been proposed tor tolbutamide. 
Phenethylbiguanide increases the glucose uptake by the rat 
diaphragm in vitro, while .uscle glycogen content is deereased 
~ lOC3l!\kC%4!Q)4JL! 
(135). A marked increase in lactic acid prOduction and a de-
crease in oxygen consumption suggests that phenethylbiguanide 
stimulates anaerobic glycolysis by inhibiting oxidative enzyme 
systems ,. 
Wick, Larson and Serit (134), using adipose tissue, have 
shown that phenethylblguanide inhibits the oxidation of glucose, 
acetate and succinate and considerably reduces fat syntheSis. 
In man, the blood pyruvate and lactate levels are raised (40) 
and there is no change in hepatic vein glucc.e, urea, pyruvate 
or laetate, nor in the oxygen consumption of the liver (119). 
Hypoglyce.ia cannot be produced in normal humans with phenethyl-
b1guanide (40), although 1n 1ntaet animals, it can easily be 
produced. The •• results suggest that the ettect. ot phenethyl-
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biguanlde are largely mediated in the peripheral tissues. 
The anoxic state suggested by these results may be due to 
the 1nhibition ot cytochrome oxidase and succinic dehydrogenase 
(116)(121), but a decrease in oxIdative phospborylation would 
have the aame result. Later work suggests that biguanlde. in-
hibit the transfer of energy-rich phosphate bonds to adenosine 
diphosphate (21)(41)(100). 
Phenethy1biguanide has also been found to increase Signi-
ficantly the levels of serum inorganic phosphate (111) whereas 
the arylsulfonylureas decrease the serum phosphate levels (37) 
(49)(01)(117), Williams et al (136) found that phenethylbi-
~-
guanide inhibited phosphorylas8 phosphatase, the enzyme cata-
lyzing the conversion of phosphorylase a to phosphorylase b. 
They also found that the compound has no effect on the activity 
of phosphorylase a or b or on the converaion of phosphorylase b 
to phosphorylase a. An inhibition of phosphorylase phosphatase 
in vitro would favor an increase in the amount ot phosphorylase 
.,... :;:;:;::;=-AJt;n 
a pre.ent in the tissue. This eould account for part ot the 
decrease in glycogen produced 1n the presence ot phenethylbi-
guanide since phosphorylase a 1s believe" to be the torm of the 
enzyme active in glycogenolysis. 
As has been mentioned on the preceding page., hypoglycemic 
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agents modify many metabollc systems. .. It has been shown by 
MCDonald and Dalldowicz (80) that several oral hypoglycemic 
agents effectively reduce the in vitro synthesis of cholesterol 
~ ! ...... +#).~. 
from acetate and mevalonate by rat llver homog.nates. On the 
other hand, Greenburg and assoclatel (53) have reported an in-
creaS8 in the level ot plasma beta llpoproteins ot diabetics 
switched trom insulin therapy to tolbutamide therapy. ThUI, the 
action of the oral hypoglycemic agents are not nearly as eon-
sistent in relieving all the metabolic d1sorders concerned w1th 
diabete. mellitus a8 is insulin. 
Protein synthesis related to diabetes has been falrly well 
studled. It has been shown that proteln synthesls is Inhibited 
during the condition ot dlabetes meilltus, and that thls Inhl-
bltlon can be reversed by Insulln (68)(103). Manehester and 
Young (77) have shown that inSUlin Increases the incorporation 
of several amino acids into rat diaphragm. Krahl (69) bas shown 
that insulin increases the uptake of 140 trom 3-l 4c-pyruvate and 
1_140-acetate into adipose tIssue proteln. Other workers have 
also shown a stimulation of protein synthesis by insulin (2)(95) 
(16) . .; f 
Whereas the action ot insulin on proteln biosynthesis has 
been widely investigated, the ettect of the oral hypoglycemic 
agents has been studled to a very llmited extent. Jarrett and 
Butterfleld (63) have shown that the invitre addition of tol-
~ Z4Q)~."""*. 
butamide decreases the incerporation of leucine-14C into protein 
and the evolution of 14C02 in .rat diaphragm. Recant and Fischer 
(101) experimented with fasted rats which were fed tolbutamide 
orally. Their results showed that the in vitro incorporation of 
.~ A{I$1;;:,C1WCAi# 
glYCine-14C into liver alice protein wa8 enhanced. 
neChatelet (34) has shown that three oral hypoglycemic 
agents (tolbutamide, chlorpropamide, and phenethylbiguanide) in 
.--
vitro all inhibit both 14002 evolution and protein 8ynthesis 
---
using leucine-140 and a rat liver homogenate. Although the 
effect did not occur at phYSiological levels of the drugs, the 
inhibition at higher levels could produce more than 50 percent 
inhibition in 14C02 evolution and in incorporation of labeled 
amino acids into protein. 
The purpose ot preparing this thesis is to investigate 
further the eftects ot the oral hypoglycemic agents on protein 
biosynthesis. This will be done by determining the etfects of 
some of these drugs on the in vitro protein biosynthesis of 
;; .......... m ··444(,. ,k .. ,.x;aa;. 
ti8sue preparations trom selected experimental animals. ThiS, 
it is hoped, will shed 80me light on the mode ot action of the.e 
drugs. 
CHAPTER III 
METHODS AND MATERIALS 
___ ~ """""",,,,,0<, ,,;c~ 
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The experimental animal was given an overdose of nembuta1 
and the tissue to be used was removed as soon as the animal was 
completely unconscious (approximately 10 to 15 mlnutes after 
injection). The tissue was washed in ice-cold buffer, blotted, 
weighed, and homogenized in cold butter. The homogenate was 
centrifuged at 100g tor 10 minute. in a ret.rlgerated centrifuge 
to remove unbroken cell., cell debris and nuclei. 
A quantity ot this homogenate was then incubated at 3100 
for one hour together with certain eO-factors, an oral hypogly-
cemiC agent, and l40.amino acids. The incubation was carried 
out in disposable center-well reaction flasks. The center-well 
contained potassium hydroxide to trap any carbon dioxide liber-
ated during the reaction. 
The incubations were stopped by the addition of 10% TCA, 
The precipitated protein was removed froll the flask and washed 
consecutively with 5% TCA, ethanol and acetone. The preCipitate 
was dissolved in O.IN NaOH and an aliquot plated out for the 
assay of radioactivity. 
The KOH was removed from the center-well and washed into 
10% bariW'A chloride. The preCipitate was filtered, washed, dried 
and assa ed tor radioactivity. 
CHEMICALS 
Adenos1ne-5'-monophosphate, sod1um salt. cal. B10chem. 
Los Angel •• , Calitornia, lot no. 53858. 
Adenosine-5'-tr1pno.phate, d1sodium salt. Cal. Biocham. 
LOI.Angele.;- calitorn1a, lot no. 52886. 
Bariwa Chlor1de. Qeneral Chemical Co., New York, N. Y., 
lot no. 14 
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Chlorpropamide, sodium salt. Charles Pfizer and Co., Inc., 
New York, N. Y., lot no. 03-422-02EPD. 
cupric sulfate pentahydrate, A. R. Xall1nkfodt Chemical Works, 
Rew York, N. Y., lot no. 4844. 
Ethylenedinitrilo tetraacetic aCid, disod1um salt. The Matheson 
Co., Inc., Norwood, Ohio, lot no. 302512. 
Oluco •• , C. P. Mallinkrodt Chemical Works, New York, N. Y., 
lot no. 4908. 
Magn.slu~ chloride, Baker Analyzed Reagent. J. T. Baker 
Chemical Co., Phillipsburg, N. J., lot no. 1-2444. 
-Nicotinamide. Sigas Chemical Co. st. Louis, Mo., lot no. 
1231-1810. 
Nicotinamide adenine dinucleotide, beta, prepared trom yeast, 
Orade III. Sigma .. Chemical Co., st. Louis, Mo., lot no. 
25B-7272. 
Phenethylbiguanide, hydrochloride. U. S. Vitamin Corp., 
New York, N. Y., lot no. 21. 
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Phosphotungstic acid, Reagent grade. Merck and Co., Inc., 
Rahway, N. J., lot no. 41118. 
potassium bicarbonate, A. R. Mallinkrodt Chemieal Works, 
New York, N. Y., lot no. 6748. 
Potalsium Chloride, A. R. Mal11nkrodt Chemical Works, New York, 
H. y., lot no. 6858. 
Potassium hydroxide, U. S. P. Allied Chemical and Dye Corp., 
New York, N. Y., lot no. G024J. 
potassium phosphate dibasie, A. R. Mallinkrodt Chemical Works, 
Hew York, N. Y., lot no. 1092. 
Potassium phosphate monobasic, A. R. Mallinkrodt Chemical 
Works, New York, N. Y., lot no. 7100. 
potassium Sodium Tartrate tetrahyd.rate, A. R. Mall inkro dt 
Chemical Works, New York, N. Y., lot no. 2367. 
Sodium Chloride, A. R. Mallinkrodt Chemical Works, New York, 
N. Y., lot no. 7581. 
Sodium hydroxide, A. R. Mallinkrodt Chemical Works, New York, 
N. Y., lot no. 7708. 
Trichloroacet1c acid, A. R. Mallinkrodt Chemieal Works, 
New York, N. Y., lot no. 29026. 
Tolbutamide, sodium salt. The Upjohn company, Kalamazoo, 
Mich1gan, lot no. OJO 11, 584-2. 
Reconstituted c14_protein Hydrolyzate. 
The labeled amino acid mixture was obtained trom Schwartz 
Bioresearch, Inc., Orangeburg, N. Y. (lot no. 6501). The amino 
-
acid mixture was supplied dissolved in O.OIN BCl to a volume ot 
1.0 m1. This was diluted with doubly, glass distilled water to 
a final concentration of 1 uC/50 ul of solution. The composition 
ot the amino acid mixture as given by the product analysis report 
supplied by the manutacturer is given in Table III. 
COMPOSITION OF SOLUTIONS 
""A·,/.-""iii< ~~ .#' J .... , 
Biuret reagent - 1.50g. ot cupric sulfate pentahydrate and 
6.0g. of potassiUll sodium tartrate were dissolved in 500 m1. ot 
distilled water. To thiS, 300 ml. ot 10; NaaH was added, and 
the resulting solution was made up to 1,000 ml. 
Butter solution - the premix was essentially that used by 
Marah (78) and DeChatelet (34). The composition of this pre.1x . 
is given 1n Table IV. Equal volumes ot the prem1x and homogenate 
were used in all incubations. Also, the premix was usually made 
up conta1ning sutficient 1sotope 80 that the volume ot premix 
used per flask contained the quantity ot labeled am1no acid de-
sired tor the incubation. In the tew experiments where the iso-
tope was added separately, it will be noted in the text. 
In the tirst tew exper1ments, homogenates were made using a 
Potter-Elvehjem type homogenizer. ~ne tissue to be studied was 
excised trom the unconscious anima1,rin.ed in ice-cold butter, 
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TABLE III 
COMPOSITION OF AMINO 
ACID MIXTURE 
SPECIFIC 
ACTIVITY ue/mc of 
AMINO ACID me/Ill !2!!. MIXTURE 
1-a1anlne-014 75 80 
l-arglnine-C14 132 50 
I-aspartic aeld-C14 113 125 
I-glutamic aeid-Cl4 200 125 
1-lso1eueine-C14 165 100 
1-leueine-CI4 225 50 
l-1yalne-C14 190 50 
1-phenylalanine-C14 165 80 
I-prol1ne-C14 115 50 
1-serine-c14 100 80 
1-threonine-C14 119 80 
1-tyroaine-c14 181 80 
I-val1ne-C14 100 50 
SUBSTAHCE 
-, . ..-. " "<,;-01,,1,. _ " 
KC1 
MgC12· 6H20 
0003 
G1uoos. 
Nieotinamid. 
EDTA 
HAD 
AMP 
ATP 
TABLE IV 
COMPOSITION OF PREMIX 
MOLARITY 
U~.~£ S. , 
0.075 
0.01 
0.015 
0.015 
0.02 
0.0003 
0.0025 
0.0020 
0.0020 
.51 
CONC. 6150 mI. 
. . 
0.280 
0.102 
0.076 
0.135 
0.122 
0.005 
0.092 
0.045 
0.062 
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blotted, weighed and ground gently in the glass-tetlon homo-
genizer for ten complete vertical strokes in three volumes of 
bufter. The homogenizer and contents were kept at oOe during 
the entire process. This preparation was then centrituged at 
700g. tor ten minute. at oOe in a refrigerated centrifuge 
(International Portable Retrigerated eentrituge~ Model PR-2, 
Serial No. 24608M). This treatment removed unbroken eells, 
cell d.ebris and nuclei. The resulting homogenate was then used 
in the incubations. 
After the first three experiment., it was tound that the 
potter-Elvehjem homogenizer could not eftectively break up the 
tough tissues from a dog or cat. It was tound that a suitable 
homogenate could be prepared in a Waring Blender. Therefore, 
in subsequent experiments, the tissue was placed in a Waring 
Blender with three volume. ot butter and minced tor 15 seconds 
at high speed. The resulting preparation was centrifuged as 
betore to prepare the homogenate. 
PROTEIN ISOLATION 
" ~"-' ,,j,...t"'=~ -rn ..... ,:;;;:: . . 4~"v""·' 
Atter stopping the incubation with l~ TeA, the protein 
precipitate was quantitatively transferred to a glass stopper 
centrifuge tube. After centrifugation, the precipitate was 
washed once with 5~ TOA, three times with 95~ ethanol, and 
three times with acetone. 
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After the final acetone wash, excess acetone was evaporated 
off and the preCipitate dissolved in 2.0 ml. ot O.lN HaOH. A 
1.0 ml. aliquot ot this solution was taken to dryness in a plan-
chet in an oven and eounted to determine the incorporation ot 
labeled amino acids into protein. The samples were counted on 
an automatiC counting assembly consisting of a Tracermatic 80-83 
scaler, a Tracerlab sa-100 Multimatic samp1. changer, and 
Tracerlab 80-66 printing Timer. No correetion was made for self-
absorption due to the BacH since the same amount of BaoH was 
present in each sample. The amount of protein present was deter-
mined by dry weight. 
14002 OOLLECTIOK AND MEASUREMElI'T 
.M. n:iC,t,.4W,t:t »,,,,_,,,ej;t:(.,~.s.,._·.,,-~I!$S~J_ ... J.,L, ~ ,}"...,.",}WZ4h ,ht.·, ,_<, •• ,"", ,K, .. ,,,, 
The incubations were carried out in 25 ml. disposable .. 
center-well flasks. The center-well contained a piece ot tilter 
paper saturated with 10% KOH to trap any C02 evolved during the 
reaction. After the incubation was stopped, the flasks were 
allowed to equilibrate so that all the evolved CO2 would be 
trapped. 
The center-well was then removed and the filter paper washed 
into a test tube containing 2 ml. ot water. Atter shaking, the 
water was decanted into ano~her tube containing 5.0 ml. ot 10% 
barium chloride. The filter paper was washed at least three 
times in this manner. The center·'well was also washed at least 
three times and these washings added to the 1&012. 
The precipitate of BaC03 was tiltered on pre-weighed discs 
of Whatman #1 tilter paper using a Tracerlab precipitation 
Apparatus, Model E8-B. The precipitate was washed three tim •• 
with "distilled water, 50-50 (v/v) ethanol-acetone, and acetone. 
The precipitate was allowed to dry betore weighing and counting. 
The sample. were counted on the same apparatus a. noted 
above. All samples were corrected tor self-absorption according 
to the tollowing equation (57): 
-uh 
I = 1-0 
""r -uh 
In this equation, I-observed activity, Io.actual activity, u~ 
0.29, and h:mg/cm2 of the plated material. The data tor the 
correction curve appears in the appendix as Table XIII and 
Figure XI. 
For a eomparison ot various experiments, it was thought 
that a measurement ot homogenate protein would be the best possi-
ble measure ot protein synthesizing capability. A modification 
of the biuret determination ot Gornall, Baradawil1 and David was 
employed (51). Blank tubes contained 4.0 ml. of biuret reagent 
and 1.0 ml. ot water. sample tubes contained 4.0 ml. of biuret 
reagent. 0.1 ml. ot homogenate and 0.9 m1. ot water. standard 
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tubes eontained 4.0 ml. ot biuret reagent and 1.0 ml. ot a solu-
tion of 1.0 to 10.0 mg/ml ot bovine serum albumin. Tne tubes 
were allowed to stand tor titteen to twenty minute. betore being 
read in a Klett-summer.on Photoelectric colorimeter titted with 
a #54 tilter. All colorimeter tubes were calibrated against 
eaCh other before use. Data"and a standard curve tor the equip-
ment used appears in Table XIV and Figure XII in the appendix. 
CHAPTER IV 
EXPIRIME1fTAL RESULTS 
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on Protein Synthesis and 14C02 Evolution in Dog Liver • 
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In this experiment, the ettect ot the concentration ot 
chlorpropamide, tolbutamide and phenethylbiguanide was measured • 
. 
Six different concentrations ot each drug were used (2, 4, 6, 8, 
10 and 15 u moles per flask). Control flasks, containing water 
were also run. Each flask contained 0.5'ml. homogenate (pre-
pared using a Potter-Elvehjem homogenizer), 0.5 ml. premix, 0.1, 
ml. isotope (2 uc/flask) and 1.0 ml. ot varying concentrations 
ot the drugs. This gave a total volume of 2.1 ml. in each flask. 
The incubation was carried out at 3roC tor one hour. The 
incubation was stopped with 10% TeA and the protein and 14C02 
were collected and prepared for counting as noted previously. 
The protein data are given in Table V, and the data are 
presented graphically in Figures VI, VII and VIII. Both activity 
and specific activity are listed and plotted. It il clearly 
evident that the three drugl all have an inhibitory effect on 
protein synthesis. It also 8eeml that chlorpropamide and tol-
butamide (both arylsulfonylureas) act ditferently from phen~thYl-
" biguanide (a guanine derivative), since the concentration cu,rves' 
tor chlorpropamide and tolbutamide are unlike that ot phenethyl-
'., . 
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TABLE V 
EXPERIMENT I: PROTEIN DATA 
G,4".-#.C*.", . :~<¥""",,,,,," •. ~ "";':S/'>'""'\~"'-~ 
sample Average Average 
uK Agent/'Flaak CPM c~tV~.e CPM CPM/mg 
.",,·-J;:_A4SJlf!\#1J4Jn.;w:;"7:;s;a:z;;t; •. ", . ,< 4" ~ ,1J3-h t';::.~JI4,,,, ! .~ ." . ..., .... ;;q 
20 a13 234 886 237 20' ~g§ 239 40 207 799 214 
40' 13 220 
6c 727 1~3 724 179 60' 721 1 5 Be ~~ 197 666 188 Be' i~ lOC 675 651 177 
lOC' 626 165 
150 5,6 1~9 548 142 15C' 5 0 1 6 
2T 791 208 801 208 
2T' 826 207 
4T 740 180 745 189 
4T' 749 197 
6T 68~ 17, 689 175 6T' 69 17 
8T 691 135 691 135 
8T' 691 135 
lOT 666 134 669 134 lOT' 671 13 
15T 634 132 638 130 
15T' 642 128 
2P 1157 2l~1 1174 242 
2P' 1191 243 4p 1177 235 1108 224 
4p' 1040 212 
6p 1004 214 1064 224 
6p' 1119 233 
8p 1112 222 1086 217 
8p' 1054 211 lOP 100 1049 211 
lOP' 1033 211 
15P 869 181 873 182 
15pt 876 183 
Controls 1105 276 
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FIGURE VI 
EXPERIMENT 1: THE Eli'PECT OF CONCENTRATION OF 
CHLORPROPAMIDE 011 THE IICORPORATIOlf OJ' AMINO 
ACIDS INTO PROTEIN. 
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FIGURE VII 
EXPERIMD'l' 1: THE EFFECT OF CONCENTRATION OF 
TOLBUTAMIDE OB THE INCORPORATION OF AMINO ACIDS 
nrro PROTEIN. 
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FIGURE VIII 
EXPERIMENT 1: THE EFFECT OF CONCEN'fRATION OF 
PHINETHYLBIOUANIDE ON THE INCORPORATION OF 
AMINO ACIDS INTO PROTEIN. 
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biguanide. This might be expected since it is thought that the 
two classes of hypoglycemic agents exert their hypoglycemic 
activity in different ways. 
Since all of the amino acids are labeled in the carboxyl 
position, all will be subject to evolving labeled C02 while 
undergoing any catabolic pathways involving decarboxylation. 
Thus, we can measure the net effect of the hypoglycemic drugs 
on the catabolic pathways of amino acid metabolism by trapping 
and collecting all the C02 evolved during the incubations. 
The 14002 data, unlik.e the protein data, are only expressed 
in terms of total cpm instead of specific activ1ty (cpm/mg). 
This is so because the amount of 002 collected (measured as 
we1ght of BaC02) does not depend entirely upon the catabolism 
-
of the labeled amino acidS. 
The Krebs cycle, tor instance, evolves C02 and thus adds 
to the net 002 evolution. Since the etfects of the hypoglycemic 
agents on this cycle and other metabolic pathways are not known, 
the interpretation at the amount at 002 collected is not easily 
elucidated. Thus, specific activity does not have a significant 
meaning in this case. 
The data for 14002 evolution is given 1n Table VI. Here 
again a definite inhibition can be .eenwith all three drugs. 
Also, a difterence in the effect of concentration of chlorpro-
pamide and phenethylbiguanide on 14002 evolution seems to show 
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TABLE VI 
EXPERIMEN'l' 1% 14C02 DATA 
M .. ""~ ,',,, .. ""C)~, • 
- ---
Sample Corrected Average 
~~L,1..~,!P.~~!l~k CP)! OPM Corrected CPM ~ 0,·.-,.,."",* ... __ 14,,_, ",..".,~ ,<.,,', ¥. ·.), .• c,~"JA .. s: -<" ,4"" -"4\",, < 
2C 35,581 54,14~ 53,498 
20' 3§,006 52,24 
4c 3 ,010 50,680 52,192 4c
' 
40,816 ~~,105 6c 38,023 ,747 49,155 
60' 38,660 49,564 
Be 31,927 49,904 48,027 Bel 34,0~2 46,151 100 33,4 2 45,866 43,768 
10C' 32,503 41,640 150 26,a96 34,5 0 34,268 150' 26, 58 33,997 
2T 38,160 49,063 47,861 
2T' 34,528 46,65~ 4T 39,7~5 49,66 48,246 4T' 35,5 7 46,825 6T 36,232 50,0~1 49,199 6T' 36,276 48'i 8 &r 31,612 ~2, 86 48,243 
BT' 34,602 3,800 
15T 24,611 31,229 31,857 
15T' 25,663 32,485 
2P 29,155 35,994 34,515 
2P' 2a,456 3~,036 4p 2 ,136 3 ,375 34,361 4pt 25,554 32,341 6p 25,173 33,042 32,735 6pt 2~/619 32,429 8p 2 ,116 29,713 29,462 8p' 2~,~04 29,151 lOP 2 , 30 33,466 30,349 
lOP' 22,054 27,233 15P 24,83 33,559 33,559 
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that these two different elasses of drugs have different modes 
of action. The results tor tolbutamide cannot be explained at 
this time. 
This experiment was basically a check of experiment 1 ex-
cept for minor changes in the incubation media. The homogenate 
again was prepared using a potter-Elvehjem homogenizer. In 
this experiment, however, the isotope was added in the premix 
so that 0.5 ml. of the premix contained 1 uc of isotope. Also 
thO. same concentrations of the hypoglycemic agents per flask 
were used except that it was added in one-half the volume. 
Therefore, the total volume of the incubation mixture was 1.5 
ml. 
The protein data is given in Table VII. This data cannot 
be tully explained. The data for chlorpropamide shows a decrease 
in protein synthesis with concentration, but the others do not. 
Also, the total cpm were very low. This would seem to indicate 
that either something poisoned the homogenate or that the homo-
genization procedure either did not sufficiently break dOVin the 
tissue or did so too completely. The chlorpropamide data seem 
to indicate that the system was not pOisoned but the homoge-
nization was poor. 
The 14C02 data for this experiment are given in Table VIII. 
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TABLE VII 
EXPERIMENT II: PROTEIN DATA 
,.cO· .:ct,' .. "..." ........ 4i4,.,~" ~
.,.,]114:>;;;;:.<1/0;:1,-;;: ..... ' '-.~ .1., ,.,','-'"'_ 
Sample Average Average 
uK Agent/F1ask CJ?M Cf.!/m,i OPM p~!ym,g. 
.' ··d:q;;tIl"l,:;:p!l(.::;:;e;;;;:¢·"m:%;_.,. ~ , ....... ~, "t.,-~.". ¢ ,,,..... _"" 
OJ? 441 110 
OP' 445 89 .. 419 98 
oP't 3~1 95 2P 3 9 ~g 406 83 2F' 422 4p 410 18 410 11 
4p' 410 15 6p 355 65 374 68 6pt 3~2 71 8p ~og 68 394 71 8p' ~~ lOP 390 381 65 
lOP' 3~ 6~ 15P ~68 §8 361 57 15pt 
OT 446 1~ OT' 411 410 77 
OT" ~81 ~3 
2T 37 Ag 420 19 2Tt 403 
4T 426 101 446 88 
4Tt 466 15 
6T ~~ 102 432 88 6ft 74 
8T ~19 62 392 71 8T' 4~~ 92 lOT 11 400 74 
lOT' 383 U l5T 361 365 71 
15T' 368 14 
OC 54g 116 oct 107 546 113 
oC" 
536 116 
20 ~~7 101 494 100 
20' ~~. 98 4C 89 467 94 
40' 493 99 
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TABLE VII (Continued) 
sample Average Average 
tIM Agent/Flask CPM ~fa!1i~j CPM 2!'11'~~1 flfW~,:;:JZSWiiJ4t:,,",;,z;;:; .l.&ill ,Gi4 ... ;:;W;;;:;:;';U)U ~ .. ." ...... "'*'.;:t4#k,.,,-",, ... 
6c 424 87 440 88 
60' 45~ 89 Be 42 81 438 83 
Be' ~~ 84 lOC ~~ 414 80 lOC' 419 
150 ~i ~5 400 77 150' 
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TABLE VIII 
EXPERIMENT II: 14002 DATA 
,,"~ .. ,,~ ,,....,.a ,.,) 4JlZ4;I(,,;:g:;:;:;et.,..#.!Q, ,,~,,-., "ct£;. 
·t]".WX·$U4J ~
Sample Correctea Average 
~'h.~~!gU!~~k CPM CPM Correctea CPM ~ r·..,.,;e#J;;;GL:~W" ·,.,..¥f!iiivij ,.kL, .. l,,i t·,,,~wr>4~·,~.;;;;:'U;,,.41"',,,"~ z;a;L" t~.JKi 
OP 31,938 34,342 Opt 35,072 50,242 51,413 
OP t f 3~,7R7 52,584 2P 2. ,5 ~ 38'r~ 37,812 2pt 28,95 36, 5 
4p 22,367 30,634 31,329 
4p' 24'479 32,024 6p 26, 10 37,730 35,099 6pt 23,042 32,468 
8p 23,274 31,882 32,116 
8p' 23,292 32,350 
lOP 20,9~0 28,311 29,298 lOP' 19,6 5 30,284 
15P 12,707 24,915 19,416 
15P' 11,829 13,916 
OT 26,714 48,571 
OT' 2~'R27 42,181 45,376 OT" 2 , 36 39,~5 2T 23,679 29, 2 37,503 
2T' 22,522 45,044 
4T 2'4,752 42,049 40,758 4T' 2 ,46~ 39,466 6T 28,70 43,497 36,438 
6T' 1'4,921 2~,329 8T 2 ,077 3 ,396 35,060 
BT' 23,220 3~,72~ lOT 1~1248 1 ,92 23,579 
lOT' 1 ,63~ 28,2~2 1ST 13,72 27,4 8 22,067 
15T' 12,180 16,685 
OC 22,~39 48,9~3 
oct 29, 51 46,6 1 47,817 
00 t , 27,100 40,448 
20 26,~16 45,372 39,186 
20' 21, 51 33,000 
4c 23,566 32,1~1 36,207 4c t 25,000 39,6 2 
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TABLE VIII (continued) 
Sample Corrected Average 
~.,~,~U!~~~.~ CPM CPM corrected CPM ~ !tiC ~.",t,~4}'AA,"'...,;::;W , ...... "L, !. !Ar.H_ ,;;::pU_·$ .. xt,:;",.::;:::z::;:;:::;z;t ... c,,,,,£ «" 
50 18,182. 3~,058 35,941 6c t 20,~65 3 ,824 
Be g' 33 16,666 26,038 Bet 1 ,9~7 35,410 lOC 16,3 4 19,980 23,056 
lOC' 18J55~ 26,131 
150 15,56 25,521 25,521 
150 1 19 .. 685 
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Again, a difference in mode of action of the two classes of 
agents could be s.en from the curves. Equating the two experi-
ments and averaging the. data allowed the plotting of curves for 
chlorpropamide and phenethylbiguan1de. These curves appear in 
Figure XIII in the appendix 
Exeeri~ent ll. !!l!. ~:tf.ct ,2£ tge ~oncent;ratior; 2! !~;!! A§ent,~ 
on Protein Synthesis and 14002 Evolution in Cat Liver, 
..... ~£ ; ......... t .. ~~ a 
The cat liver homogenate was prepared in a Potter-Elvehjem 
homogenizer The isotope was added in the premix so that 05 ml 
of premix contained 1 uc of isotope The total incubation 
volume was 1.5 mI. 
The protein data is given in Table IX. As in the previous 
experiment, the protein data is not significant. Again, the 
total cpa were very low and the data showed no uniform decrease 
in protein synthesis with increased concentration of the drugs. 
This was probably due to incomplete homogenization since the 
cat liver was very tough. 
The 14002 data are presented in Table X and in Figure IX. 
The curves for tolbutamide and chlorpropamide were almost identi-
cal and there was a marked difference between these curves and 
the one tor phenethylbiguanide. Again this shows the difference 
in the mode of action of the two classes of drugs. 
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TABLE IX 
EXPERIMENT III: PROTEIN DATA 
il'~""fo-,L.e, ,,::au< .. 4$u.t¥:,u.:;.j ....... ~
.. 4,..::;: ... "..".$""",,0 ~ ....... ~,,* ~
Sample Average Average 
\1M Agent/Flaak ePM 9ttVS CPM C.~L~~d ~~~" (,a;t;:,,,,W,,tJ4ij.:r$,,..,,,"" ... ~ '!'!t· ........ t.£):M,', •. AiJc,.., 
OP 554 113 
OP' 608 
'a':' 122 566 113 OP" ~g 1~~ 2P 477 94 
2P' 465 ~~ 4p 455 t§g 88 6p 43~ 76 76 8p 395 76 ~95 76 lOP. 415 +4 15 17 15P 38~ 315 73 15pt 36 12 
OT 503 101 OTt R~~ 110 538 103 OT't 99 
2T' 413 105 4A3 l~R 4T 503 19~ 4 2 4T' 461 
6T 443 96 536 109 
6T' 630 121 
BT 514 104 540 100 
BT' ,06 9'4 lOT 91 ~8 412 91 lOT' 4~2 15T 4 1 ~~ 474 91 15T' 461 
OC 638 114 
oct 542 115 599 120 oct , 61~ 1~1 2C 65 1 3 633 136 
20' 607 . 129 
4c 562 120 556 111 
4c' 550 115 
6c 529 110 529 110 Be 531 110 521 102 Be' ~05 §g 1CC 82 481 98 loe I 419 100 
Sample 
~.,P:~,~~al.a~lt 
150 
15C f 
CPN 
~
561 
516 
TABLE IX (Continued) 
C~(9 
109 
103 
Average 
CPN 
538 
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Average 
CPM/mg 
•. '. . "'. t 
106 
71 
TABLE X 
EXPERIMENT III: 14C?2 DATA 
Sample Corrected Average 
u)f",~,~~,~~a1aSlt CPM CPM Corrected CPM ~ '.'," ';"F+" •• 4- . , -..-; .', ' 
OP 41,096 52,020 
OP' 37 .. 300 47,897 51,089 
oP't 35,211 5~,3~0 2P 2~,149 3 ,7 4 38,594 2Ft 2 ,882 38,403 
4p 23,319 29,506 29,506 6p 20,761 29,241 30,810 
6p' 22,989 32,379 8p 20,590 27 ,4~3 26,548 8p' 20,257 25,6 2 
lOP 18,293 23,156 23,333 
lOP' 18,~37 23,~09 
15P 1~, ~6 23, 79 26,416 15P' 1 ,7 5 29,352 
OT 39,735 51,604 
OT' 39,~79 R2,078 50,905 OT't 32, 59 9,043 
2T 36,101 4~,501 47,929 
2T' 31,915 4 ,356 
4T 33,670 44,303 45,040 
4T' 29,297 45'~!7 6T 27,95~ 3§, 5 35,848 8T 27,64 3 ,005 37,060 
BT' 27,447 36,114 
lOT 27,149 35,722 36,217 
lOT' 26,4~2 36,711 
15T 16,1 4 22,142 22,364 
15T' 16,713 22,589 
OC f 34,483 49,261 49,353 
OC" 37,083 49,444 
2C 35,41~ 45,9~9 44,144 2C f 33,40 42,2 ~ 
4c 31,024 ~9,77 42,849 40' 34,443 5,~24 60 31,847 40, 29 37,879 
6c t 24,450 ~4'429 Be 29,528 0, 49 37,753 
Sample 
~p~~~n~I!:~.alk 
Be' 
100 
lOC' 
150 
15C' 
CPM 
26,293 
23,678 
26,110 
11,186 
15,732 
TABLE X (Continued) 
Correete'd 
OPM 
35,057 
29,972 
35,284 
14,527 
21,551 
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Average 
Corrected CPM 
~.~), .'t\.J,;S:: .. S:;;'· 
32,628 
18,039 
v 
0 
x 
~ 
a.. 
0 
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4.5 
3.5 () 
2.5 
0 
2 4 6 8 10 15 
~M Hypoglycemic Agent 
FIGURE IX 
EXPERIMENT 3: THE EFFECT OF CONCENTRATION OF 
• CHLORPROPAMIDE (.), TOLBUTAMIDE (0) AND 
PHENETHYLBIGUANIDE \ 0) ON THE EVOLUTION OF 
14002 USING CAT LIVER HOMOGENATE. 
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EXR~irij,!!~pt 4: 'ttec~ ot Ho~~genization o~ Protein Synthesis. 
The previous two experiments seemed to show a need tor a 
better method ot homogenization. Theretore, several methods 
were compared to see which gave the most active homogenate. 
For the experiments, five female albino rats were used. 
They were sacrificed by decapitation and their livers removed 
immediately and placed in ice-cold butter. Each liver was dis-
sected into tour equal parts (equal to the nearest 0.1 g.). 
Four methods of homogenization were used. Therefore, each of 
the four difterent homogenates contained one quarter ot each of 
five rat livers. 
The only convenient methods ot homogenization available 
were the Potter-Elvehjem homogenizer and the Waring Blender. 
The tour methods therefore utilized one or both ot these methods. 
The first homogenate was made in a potter-Elvehjem homogenizer 
tor ten full vertical strokes. The second homogenate was made 
by tirst blending the tissue tor 15 seconds in the Waring 
Blender and then homogenizing this blend in the Potter-Elvehjem 
homogenizer for tive full vertical strokes. The third homo-
genate was made by blending for 15 seconds in the Waring Blender. 
The tourth homogenate was made by blending for 30 seconds in the 
Waring Blender. 
Homogenate protein was determined tor each difterent homo-
genate. It was found that they were all comparable in protein 
15 
content in that all homogenate protein concentrations remained 
within three mg/ml. 
The homogenates were all treated exactly alike after the 
homogeniaation process. The incubation mixture contained 0.5 
ml. of one of the homogenates, 0.5 ml. of premix and 0.1 m1 . 
. or 2 ue of isotope. The incubation was run exactly as the 
others. 
The data tor protein synthesis and 14002 evolution are'·' 
given in Table XI. Looking at the 14002 data, it appears that, 
while the fourth homogenate is the most active, there is not a 
great deai of difference between any of them. However, when 
one looks at the protein data, one can see that the method of 
homogenization is very critical. It is apparent that a 15 se-
cond blend or use of the potter-ElvehJem homogenizer. alone are 
the best methods. Since the potter-ElvehJem method did not wor 
previously, the blending method was used in subsequent experi-
ments. 
~:l!!~~!~;~ 2l 'f~! !~t!;<:~j ?t ~~! ~.R~,~!I!~:'~~lQ?~ ?f !~~~~ ~§!ll:~ 
on 14002 Evolution in Rabbit Liver. 
~ jlJ",WJW~$44IJ4V.\! ~"¢:;,,,,¢; p~~>p;;alr ,M ~- "1.">,.4,,,.,.-,%..,;:;;4I\"!!I:~ 3 .. "H ,,;;t~,},.,,,,t,,,; 
The liver was homogenized as stated in experiment 4. The 
isotope was again added in the premix so that 0.5 ml. ot pre-
mix contained 2 uc of labeled amino aCid .. The concentration 
of the hypoglycemic agents used were the same but were added in 
herefore the total incubation volume 
Homogenate 
'·iIi."""'_ 4 ZW"';;£",·"JilZ 
First 
First' 
First. t 
Second 
Second' 
Second f , 
Third 
Third' 
Third' , 
Fourth 
Fourth' 
Fourth" 
TABLE XI 
EXPE~~.!!.:. 14C02 DAT.IA, 
. '" ", ., \.' 
EXPERIMENT IV: PROTEIN DATA 
~,,..L,W!#z:;: .. lwtes:-: ~ .. !)Jt#~.,;W;.,{Att4tA ~
g~&~~ 
Average 
CPf.{ CPM 
~ .i-M::U .. ,_",~S A,Vt·, .... ,· 
1~49 1 32 314 296 1968 
2125 33~ 149~ 22 162 243 1601 
1681 255 
2105 319 
2109 320 2128 
2169 329 
1082 152 . 
1065 150 1080 
1094 154 
76 
Average 
2.~~tf!ltt .. 
316 
261 
323 
152 
77 
was 1.1 mI. 
The 14C02 data are given in Table XII and presented graphi-
cally in Figure X. 
The ettect of phenethylbiguanide in the rabbit, as inter-
preted by the concentration curves, is similar to that in the 
dog and cat. However, the effect of tolbutamide and chlorpropa-
mide seems to be different. Whereas these two agents gave linear 
curves in the dog and cat, the curves tor the rabbit liver were 
more pronounced at first and then tended to level off at higher 
concentrations. 
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TABLE XII 
EXPERIMENT V: 14C02 DATA 
, (. ,?, ".,.s .W4, .. " .. ~ )",,,-~.J. .. J,,,,Z ~
sample Corrected Average 
uM A~enta:lask ON 01'. Corrected CPM 
'" ' .• t"IiiI!.t=.~ ... ~ . .,.., ...... , ,,·-M"~ -.:r" . ."-,,,' • J,_ .. ~ ,4") 
01' 39,8~4 48,065 48,065 
2P 21,9 6 25,80~ 26,532 
2F' 23,166 27,25 
41' 16,575 19,0§2 20,516 
41" 18,903 21,9 0 
61' 18,726 21,774 20,615 
61" 16,538 19,~6 81' 16,760 1~, 8 19,151 81" lR,991 1 ,813 101' 1 ,550 17,117 19,573 
lOP' 14,402 22,028 15P 1 ,5~0 18,680 18,113 
15P' 14,3 8 17,546 
OT 41,609 52,670 54,324 
OTt 43,10~ 5g,978 2T 3C,73 3 ,593 35,330 
2Tt 2~,297 34,066 4T 2 ,410 28,718 29,209 
4TI 24,651 29,700 
6T 19,000 22,619 20,624 
6'1" 16,207 18,62~ 
8'1' 17,212 19,,,(8 19,710 
8T' 14,074 19,625 lOT 1 ,191 16,126 19,394 
lOTI 17,900 22,658 
15'1' 12,557 14,269 14,176 
15'1'1 11,971 14,083 
OC 37,221 43,790 43,571 
OC' 36,764 43,252 
2C 29,732 37,636 36,208 
2C' 29,910 34,77~ 40 21,008 24,42 25,942 
40' 23,886 27,455 
6c t 20,661 24,257 24,257 
Be 18,579 21,355 21,355 
100 18,462 23,077 19,502 
1OC' 13,856 15,926 
sample 
uM Agent/Flask 
, ' • :'-""~ .", ' ~-. ;:;t. ""·Ji..\.-,,,4·, ~ .. , 
150 
150 t 
TABLE XII (Continued) 
CPM 
-.-.-
11,737 
12,161 
Corrected 
cm 
13,491 
13,819 
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Average 
Corrected CPM 
13,655 
5.0 
v 
o 4.0 
x 
~ 3.0-
U 
2.0-
I I I 
2 4 6 8 10 15 
~ M Hypoglycemic Agent 
FIGURE x 
EXPERIMElrr 5: THE EFFECT OF OONCDTRATION OF 
OHLORPR.OPAMIDE (.) ~ TOLBUTAMIDE (ct), AND 
PHENE'fHYLBIGUANIDE \ 0) ON THE EVOLUTION OF 
14002 USING RABBIT LIVER HOMOGENATE. 
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SUMMARY AND CONCLUSIONS 
.<~ -
The effect of the hypoglycemic compounds, chlorpropamide, 
tolbutamide and phenethylbiguanide, on protein synthesis and 
the catabolism of amino acids was investigated using tissue 
homogenates,n'ecessary cO,-factors, and radioactive amino acids. 
The results reported in this thesis show that the three compounds 
all inhibit both protein synthesis (as measured by the incorpora-
tion of amino acids into protein) and the catabolism of amino 
acids (as measured by the evolution of 14C02 from the incubation 
edia). Dog, cat and rabbit liver homogenates yielded similar 
results The data are also in agreement with the reports of 
eChatelet (34) who used rat liver homogenates. 
Chlorpropamide and tolbutamide seem to aftect the catabolism 
nd incorporation ot amino acids in the same way while phenethyl-
biguanide seems to act in a difterent manner, This could be 
xpected since the two classes of drugs act in difterent ways as 
ypoglycemic agents. Chlorpropamide and tolbutamide inhibition 
t l4C02 evolution (amino acid catabolism) is linear with respect 
to concentration for both dog and cat liver homogenates. Their 
inhibitory effects in the rabbit are not linear, being more in-
first and then leveling off at higher concentrations. 
since a mixture of labeled amino acids was used, this 
epresents only a gross inhibition and the com~ounds' eftects on 
catabolism ot individual amino acids cannot be redicted. 
These drugs also inhibit the incorporation of amino acids into 
protein This inhibition is pronounced at first and then levels 
otf at higher concentrations ot the agents. 
The inhibition of 14c02 evolution by phehethylbiguanide is 
pronounced at first but then tends to level off at the higher 
concentrations The inhibition ot incorporation of amino acids 
is nearly linear and not very great at first and then at higher 
concentrations the inhibition seems to become more pronounced. 
The mechanisms of action of the two classes of drugs as 
exemplified by the concentration curves are evidently markedly 
different The results and concentrations curves presented here 
are in general accord with the results obtained using rat liver 
homogenates (34), The mechanisms of action of the three drugs 
seem to be the same, at least in the dog, cat and rat liver 
systems. Whether or not the ditference in the curves for the 
efteet of chlorpropamide and tolbutamide on 14C02 evolution from 
the rabbit system infers a different mode of action cannot be 
stated. 
Phenethylbiguanide has been shown both in this theais and 
by DeChatelet (34) to inhibit both the in vitro synthesis of 
- , 
protein and the catabolism of amino acids in homogenates of 
dog, cat, rabbit and rat livers. However, Ungar !! al (120) 
has reported that this agent does not act as a hypoglycemic agent 
~ ~ in the dog while it does in the eat, rabbit and rat. 
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'Therefore, it seems that the two activities of phenethylbiguanid~ 
• the hypoglycemic activity and its inhibitory effect on amino acid 
metabolisM are independent of each other. 
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APPENDIX 
Kg BaC03 
• $ 
0.0-0.4 
0.5-0.6 
0.7 
0.8-0.9 
1.0-1.5 
1.6-1.7 
1.8-1.9 
2.0-2.1 
2.2-2·3 
2.4-2.6 
2.7-2.9 
3.0-3.1 
3.2-3.4 
3.5 
3.6-3.8 
~.9-4.1 
.2-4.4 
4.5 
4.6-4.9 
5.0-5.2 
5.3-5.4 
5.5-5.7 
5.8-6.0 
6.1-6.3 
. 6.4-6.6 
TABLE XIII 
SELF-ABSORPTION CORRECTIONS FOR BaC03 
~ .w;::::::;;::; 1 .;s;;:u:;.v:U.;;'" JQiIi!UW4 aM¥14 $$ 4 '" ~ ....... :;;:W;;u::::::;;;;. 
1/10 Kg B&C03 
-
z ;-= 
1.00 6.7-6.8 
0.98 6.9-7.2 . 
0.9~ 7.~-~.7 0.9 7. - .0 
0.93 8.1-8.3 
0.92 8.4-8.6 
0.91 8.7-8.9 
O.~O 9.0~9.g 
o. ~ 9.4-9. 0.8 9.7-10.0 
0.87 10.1-10.4 
0.86 10.5-10.8 
0.85 10.9-11.2 
0.84 11.3-11.6 
0.83 11.7-12.1 
0.82 12.2-12.4 
0.81 12.5-12.9 
0.80 13.0-13.~ 
• 0.1a 13.4~1~. 0.7 13.9-1.1 
0.71 15.0 
0.76 15.5-15.8 
0.75 16.0 ' 
0.74 17.0 
0.73 20.0 
.85 
1/10 
-0.72 
0.71 
0.70 
0.6~ 0.6 
0.67 
0.66 
0.6~ o 6 . . , 
0.63 
0.62 
0.61 
0.60 
0.5~ 0.5 0.57 . 
0.56 
0.5~ 0.5 . 
. 0.53 
0.51 
O.~O 
o. 9 
0.47 
0.43 
Reproduced from: DeChatelet, L. R , TheSiS, Loyola University, 
June, 1965. 
1.0-~. 
0", 
0.8- 0" 
0", 
° ~o 
0.6- ~o 
~o 
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FIGURE XI 
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.............. 0 
~o 
16 20 
SELF-ABSORPTION CORRECTION CURVE FOR !aCOS 
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TABLE XIV 
STANDARD CURVE DATA FOR PROTEIN DETERMINATION 
--
Mg Protein Klett Units Average Standard 
Deviation 
0.5 16.0 
0.5 14.0 15.0 1.0 
0.5 15.0 
1.0 28.5 
1.0 31.0 30.0 1.3 1.0 30.5 
1.5 4~.5 44.1 1.5 4 .0 0.8 
1.5 44.5 
2.0 60.0 
2.0 64.0 61.1 2.1 
2.0 61.0 
2.5 1~.0 2.5 1 .5 11.2 1.3 2.5 16.0 
3.0 92.0 
3.0 92.5 91.8 0.8 
3.0 91.0 
4.0 123.0 
4.0 119.0 121.2 2.0 4.0 121.5 
5.0 152.0 
5.0 150.0 152.0 2.0 
5.0 154.0 
Reproduced from: DeChate1et, L. R. , Theais, Loyola 
University, June, 1965. 
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FIGtmE XII 
STANDARD CURVE FOR PROTEIN ANALYSIS. 
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FIGURE XIII 
THE EFFECT OF CONCENTRATION OF CHLORPROPAMIDE 
( .) AND PBENETHYLBIGUANIDE (0) ON 14C02 
EVOLUTION USING oon LIVER HOMOGENATE. AVERAGE 
OF EXPERIMElfrS 1 AIm 2. 
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